Asset profile
Ulotaront
Small molecule
Evidence outlook · lead readout
NCT04092686 · Schizophrenia
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT04092686: This was a randomized, quadruple-masked, placebo-controlled trial with 464 participants and a clinical symptom-score primary endpoint (PANSS). The primary result was mixed: the 100 mg dose was statistically better than placebo, but the 75 mg dose was not, so the findings provide meaningful but incomplete evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 37 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ulotaront: this drug | Phase 3 | Small molecule | TAAR1 (trace amine-associated receptor 1) | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Haloperidol | Approved | Small molecule | Dopamine D2 receptor (antagonist) | ||
| Iloperidone (PD Psychosis Use) (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Loxapine (Adasuve) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2028 (3)
March 2028 (1)
October 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.